INTRODUCTION: The aim of the present study is to review the economic burden of varicella disease and the benefit of universal varicella vaccination in different settings pending its implementation in all Italian regions. MATERIALS AND METHODS: Research was conducted using PubMed, Scopus and ISI databases. Score quality and data extraction were performed for all included studies. RESULTS: Twenty-three articles met the criteria: 15 cost-effectiveness, 8 cost-benefit and one cost-utility analysis. Varicella vaccination could save the society from €637,762 (infant strategy) to 53 million annually (combined infant and adolescent strategy). The median and the mean quality scores resulted in 91.8% and 85.4% respectively; 11 studies were considered of high quality and 12 of low quality. DISCUSSION: The studies are favorable to the introduction of universal varicella vaccination in Italy, being cost saving and having a positive impact on morbidity. The quality score of the studies varied greatly: recent analyses were of comparable quality to older studies.
INTRODUCTION: The aim of the present study is to review the economic burden of varicella disease and the benefit of universal varicella vaccination in different settings pending its implementation in all Italian regions. MATERIALS AND METHODS: Research was conducted using PubMed, Scopus and ISI databases. Score quality and data extraction were performed for all included studies. RESULTS: Twenty-three articles met the criteria: 15 cost-effectiveness, 8 cost-benefit and one cost-utility analysis. Varicella vaccination could save the society from €637,762 (infant strategy) to 53 million annually (combined infant and adolescent strategy). The median and the mean quality scores resulted in 91.8% and 85.4% respectively; 11 studies were considered of high quality and 12 of low quality. DISCUSSION: The studies are favorable to the introduction of universal varicella vaccination in Italy, being cost saving and having a positive impact on morbidity. The quality score of the studies varied greatly: recent analyses were of comparable quality to older studies.
Authors: Nancy Thiry; Philippe Beutels; Francesco Tancredi; Luisa Romanò; Alessandro Zanetti; Paolo Bonanni; Giovanni Gabutti; Pierre Van Damme Journal: Vaccine Date: 2004-09-09 Impact factor: 3.641
Authors: Peter Wutzler; Paolo Bonanni; Margaret Burgess; Anne Gershon; Marco Aurélio Sáfadi; Giacomo Casabona Journal: Expert Rev Vaccines Date: 2017-07-13 Impact factor: 5.217
Authors: Alies van Lier; Anna Lugnér; Wim Opstelten; Petra Jochemsen; Jacco Wallinga; François Schellevis; Elisabeth Sanders; Hester de Melker; Michiel van Boven Journal: EBioMedicine Date: 2015-08-08 Impact factor: 8.143
Authors: R Gasparini; F S Mennini; D Panatto; P Bonanni; A Bechini; W Ricciardi; C DE Waure; A Marcellusi; A Cicchetti; M Ruggeri; S Boccalini Journal: J Prev Med Hyg Date: 2015
Authors: Oliver Damm; Bernhard Ultsch; Johannes Horn; Rafael T Mikolajczyk; Wolfgang Greiner; Ole Wichmann Journal: BMC Public Health Date: 2015-06-05 Impact factor: 3.295
Authors: Katsiaryna Holl; Christophe Sauboin; Emanuele Amodio; Paolo Bonanni; Giovanni Gabutti Journal: BMC Public Health Date: 2016-10-21 Impact factor: 3.295